Collectively, these data reveal that PDOs do not always recapitulate the original patient’s drug responses, suggesting that tumor extrinsic factors, such as stromal environment, might contribute to treatment responses, particularly in cases where the PDOs showed sensitivity to ER and CDK4/6 targeting therapies, but the patient relapsed on these therapies. This evidence concerns the gene ESR1 and neoplasm.